Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study.
DCAT
Lung SABR
Radiation pneumonitis
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
22 Feb 2023
22 Feb 2023
Historique:
received:
23
01
2023
accepted:
13
02
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
25
2
2023
Statut:
epublish
Résumé
Stereotactic ablative radiotherapy (SABR) is a validated treatment for early stage lung cancer and pulmonary metastases. It provides a high local control rate with low symptomatic toxicities. Recently, Dynamic Conformal Arc Therapy (DCAT), a delivery option that differs from conventional DCA, has been implemented in the Monaco Treatment Planning System for SABR. The aim of the study was to report clinical outcomes and toxicities for patients treated for lung SABR with this new technique. We retrospectively identified adult patients treated for primary or secondary lung tumors with DCAT-SABR and reported their clinical, radiological, histological characteristics and dosimetric parameters. Total dose was delivered in 3 or 5 fractions for 95% of patients and prescribed on the 80% isodose line to the PTV periphery. 145 patients met inclusion criteria for a total of 152 lesions with a median follow up of 12 months. Local control for the irradiated site was 96.7% at 1 year. Overall survival was 93.1% at 1 year. Mean prescription dose in BED Lung SABR for primary or metastatic lung tumors using dynamic conformal arc therapy provides efficient results of local control and low lung toxicities, similar to other SABR techniques. SABR using DCAT is a safe technique to treat lung lesions, allowing intra-fraction motion limitation, potentially higher OARs protection and a shortened beam delivery.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic ablative radiotherapy (SABR) is a validated treatment for early stage lung cancer and pulmonary metastases. It provides a high local control rate with low symptomatic toxicities. Recently, Dynamic Conformal Arc Therapy (DCAT), a delivery option that differs from conventional DCA, has been implemented in the Monaco Treatment Planning System for SABR. The aim of the study was to report clinical outcomes and toxicities for patients treated for lung SABR with this new technique.
METHODS
METHODS
We retrospectively identified adult patients treated for primary or secondary lung tumors with DCAT-SABR and reported their clinical, radiological, histological characteristics and dosimetric parameters. Total dose was delivered in 3 or 5 fractions for 95% of patients and prescribed on the 80% isodose line to the PTV periphery.
RESULTS
RESULTS
145 patients met inclusion criteria for a total of 152 lesions with a median follow up of 12 months. Local control for the irradiated site was 96.7% at 1 year. Overall survival was 93.1% at 1 year. Mean prescription dose in BED
CONCLUSION
CONCLUSIONS
Lung SABR for primary or metastatic lung tumors using dynamic conformal arc therapy provides efficient results of local control and low lung toxicities, similar to other SABR techniques.
ADVANCES IN KNOWLEDGE
CONCLUSIONS
SABR using DCAT is a safe technique to treat lung lesions, allowing intra-fraction motion limitation, potentially higher OARs protection and a shortened beam delivery.
Identifiants
pubmed: 36814265
doi: 10.1186/s13014-023-02227-2
pii: 10.1186/s13014-023-02227-2
pmc: PMC9948312
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
36Informations de copyright
© 2023. The Author(s).
Références
J Cancer Res Clin Oncol. 2020 May;146(5):1263-1271
pubmed: 32095885
Med Phys. 2003 Dec;30(12):3206-16
pubmed: 14713087
Transl Lung Cancer Res. 2020 Apr;9(2):348-353
pubmed: 32420074
Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):457-62
pubmed: 21035956
J Med Phys. 2020 Jul-Sep;45(3):143-147
pubmed: 33487926
Radiother Oncol. 2020 Jan;142:217-223
pubmed: 31767472
BMC Cancer. 2019 Feb 26;19(1):173
pubmed: 30808323
Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1357-1366
pubmed: 27325482
Phys Med. 2016 Apr;32(4):600-6
pubmed: 27061871
BMC Cancer. 2020 Oct 14;20(1):997
pubmed: 33054721
Br J Radiol. 2020 Jan;93(1105):20190596
pubmed: 31625759
Radiother Oncol. 2013 Dec;109(3):498-504
pubmed: 24231237
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Rep Pract Oncol Radiother. 2020 Jul-Aug;25(4):667-677
pubmed: 32565744
Radiother Oncol. 2017 Jul;124(1):11-17
pubmed: 28687397
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
Cancer Res Treat. 2020 Oct;52(4):1188-1198
pubmed: 32718145
Ann Oncol. 2014 Aug;25(8):1462-74
pubmed: 24562446
J Radiat Res. 2021 Mar 10;62(2):338-345
pubmed: 33480428
Radiother Oncol. 2021 Mar;156:231-238
pubmed: 33096168
Radiother Oncol. 2009 Dec;93(3):645-53
pubmed: 19926153
Radiother Oncol. 2021 Mar;156:153-159
pubmed: 33333139
JAMA Oncol. 2018 Sep 1;4(9):1263-1266
pubmed: 29852037
J Appl Clin Med Phys. 2014 Sep 08;15(5):4898
pubmed: 25207575
Phys Med Biol. 2006 Nov 21;51(22):5785-807
pubmed: 17068365
J BUON. 2019 Mar-Apr;24(2):838-843
pubmed: 31128044
Int J Radiat Oncol Biol Phys. 2021 May 1;110(1):172-187
pubmed: 30496880